# Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

> **NCT00536809** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Neoplasms, Colorectal

## Interventions

- **DRUG:** lapatinib
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00536809
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-26
- **Primary completion:** 2008-10-31
- **Final completion:** 2008-10-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536809, "Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00536809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*